NCT05214677

A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809

A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of DW1809 and DW1809-1 in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Daewon Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study

Conditions

• Osteoarthritis
• Rheumatoid Arthritis
• Back Pain
• Acute Upper Respiratory Tract Infection

Interventions

Type	Name	Description
DRUG	DW1809	pelubiprofen 30mg
DRUG	DW1809-1	pelubiprofen 30mg (PELUBI tab.)

Timeline

• Start date: 2020-08-15
• Primary completion: 2020-09-07
• Completion: 2020-09-07
• First posted: 2022-01-31
• Last updated: 2022-01-31

Locations

1 site across 1 country: South Korea